Table 1 Demographic and clinical characteristics of patients with PCP according to respiratory failure
Total (n = 50) | Non-severe PCP (n = 23) | Severe PCP (n = 27) | P-value | ||
|---|---|---|---|---|---|
Age (years) | 47.22 ± 14.35 | 41.4 ± 14.7 | 52.2 ± 12.3 | 0.007* | |
Male (n, %) | 28 (56.0%) | 13 (56.5%) | 15 (55.6%) | 1.000 | |
BMI | 21.81 ± 3.33 | 20.4 ± 2.8 | 23.0 ± 3.3 | 0.005* | |
Underlying disease Diabetes mellitus Hypertension Tuberculosis Hepatitis B virus Hepatitis C virus | 10 (20.0%) 44 (88.0%) 3 (6.0%) 4 (8.0%) 1 (2.0%) | 5 (21.7%) 21 (91.3%) 1 (4.3%) 2 (8.7%) 0 | 5 (18.5%) 23 (85.2%) 2 (7.4%) 2 (7.4%) 1 (3.7%) | 1.000 | |
Causes of transplantation Hypertension Diabetes mellitus Glomerulonephritis Polycystic kidney disease Unknown | 6 (12.0%) 11 (22.0%) 13 (26.0%) 4 (8.0%) 16 (32.0%) | 3 (13.0%) 3 (13.0%) 8 (34.8%) 0 9 (39.1%) | 3 (11.1%) 8 (29.6%) 5 (18.5%) 4 (14.8%) 7 (25.9%) | 0.139 | |
Type of kidney donation Living related donor Living unrelated donor Deceased donor | 25 (50.0%) 15 (30.0%) 10 (20.0%) | 14 (60.9%) 6 (26.1%) 3 (13.0%) | 11 (40.7%) 9 (33.3%) 7 (25.9%) | 0.324 | |
Type of immunosuppressant Tacrolimus Cyclosporine Mycophenolate mofetil Sirolimus | 35 (70.0%) 15 (30.0%) 41 (82.0%) 2 (4.0%) | 16 (69.6%) 7 (30.4%) 18 (78.3%) 2 (8.7%) | 19 (70.4%) 8 (29.6%) 23 (85.2%) 0 | 1.000 | |
Co-infection Cytomegalovirus BK virus | 18 (36.0%) 10 (20.0%) | 7 (30.4%) 4 (17.4%) | 11 (40.7%) 6 (22.2%) | 0.645 0.943 | |
ABO incompatible | 13 (26.0%) | 6 (26.1%) | 7 (25.9%) | 1.000 | |
Re-transplantation | 3 (6.0%) | 0 | 3 (11.1%) | 0.293 | |
Incidence of TMP/SMX Prophylaxis failure | 12 (24.0%) | 4 (17.4%) | 8 (29.6%) | 0.498 | |
Time from onset of symptom to hospital admission (days) | 7.3 ± 6.0 | 9.1 ± 7.6 | 5.8 ± 3.8 | 0.063 | |
Time from transplantation to PCP (months) | 18.1 ± 18.8 | 23.4 ± 24.9 | 13.7 ± 9.9 | 0.090 | |
Time from discontinuation of TMP/SMX to PCP (months) | 8.9 ± 14.0 | 12.8 ± 19.9 | 5.6 ± 2.7 | 0.101 | |
HLA-A, B, DR mismatch | 2.9 ± 1.5 | 2.3 ± 1.1 | 3.4 ± 1.7 | 0.011* | |
Total lymphocyte count (mm3) (normal range: 800-4,000 /mL) | 755.0 ± 421.5 | 970.7 ± 408.3 | 571.2 ± 342.7 | 0.001* | |
History of acute rejection treatment within 1 year | 19 (38.0%) | 6 (26.1%) | 13 (48.1%) | 0.190 | |
Use of rituximab | 19 (38.0%) | 6 (26.1%) | 13 (48.1%) | 0.190 | |
Change of second-line antibiotics | 25 (50.0%) | 10 (43.5%) | 15 (55.6%) | 0.570 | |
Use of adjunctive corticosteroid | 34 (68.0%) | 10 (43.5%) | 24 (88.9%) | 0.002* | |
Length of hospital stay (days) | 39.94 ± 68.38 | 17.1 ± 9.9 | 59.4 ± 88.8 | 0.001* | |
Mortality | 7 (14.0%) | 0 | 7 (25.9%) | 0.026* | |